publication . Doctoral thesis . 2013

Diagnosis and prognosis of brain tumors in clinical trials

Gorlia, Thierry;
Open Access English
  • Published: 13 Nov 2013
  • Publisher: Erasmus University Rotterdam
  • Country: Netherlands
Abstract
textabstractAccording to the Central Brain Registry Of The United States (CBTRUS) statistical report (February 2012) the incidence rate of all primary non malignant and malignant brain and central nervous system tumors is 19.89 cases per 100.000 (11.58 for non-malignant tumors and 7.31 for malignant tumors). Malignant brain tumors account for only 1% to 2% of all adult cancers. As a comparison, in 2012, the incidence of women breast cancer was 121.2 (per 100.000). Tumors of neuroepithelial tissue are the most frequent malignant brain tumors with an incidence rate of 6.16. The most common tumor of neuroepithelial tissue is the glioblastoma (GBM) with an incidence...
Subjects
free text keywords: brain tumors, neurology, prognostic factors
Related Organizations
Download from

1. Louis DN, Ohgaki H, Wiestler OD, et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109, 2007. [OpenAIRE]

2. Miller CR, Dunham CP, Scheithauer BW, et al.: Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed highgrade gliomas. J Clin Oncol 24:5419-5426, 2006. [OpenAIRE]

3. Nelson JS, Tsukada Y, Schoenfeld D, et al.: Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 52:550-554, 1983. [OpenAIRE]

4. Fulling KH, Garcia DM: Anaplastic astrocytoma of the adult cerebrum. Prognostic value of histologic features. Cancer 55:928-931, 1985. [OpenAIRE]

5. Kouwenhoven MC, Gorlia T, Kros JM, et al.: Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol 11:737-746, 2009.

6. Hegi ME, Janzer RC, Lambiv WL, et al.: Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol 123:841-852, 2012. [OpenAIRE]

7. Kros JM, Gorlia T, Kouwenhoven MC, et al.: Panel review of anaplastic oligodendroglioma from EORTC trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss and correlations with outcome. J Neuropathol Exp Neurol 66:545-551, 2007.

8. Gorlia T, van den Bent MJ, Hegi ME, et al.: Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29-38, 2008.

9. van den Bent MJ, Hartmann C, Preusser M, et al.: Interlaboratory comparison of IDH mutation detection. J Neurooncol, 2013.

10. Weller M, Stupp R, Reifenberger G, et al.: MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39-51, 2010.

11. Woehrer A, Sander P, Haberler C, et al.: FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice - a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS). Clin Neuropathol 30:47-55, 2011.

12. van den Bent MJ, Gravendeel LA, Gorlia T, et al.: A hypermethylated phenotype in anaplastic oligodendroglial brain tumors is a better predictor of survival than MGMT methylation in anaplastic oligodendroglioma: a report from EORTC study 26951. Clin Cancer Res, 2011. [OpenAIRE]

13. Erdem-Eraslan L, Gravendeel LA, de Rooi JJ, et al.: Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain. Tumors: A Report From EORTC Study 26951. J Clin Oncol (in press).

Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue